Shares of AstraZeneca Pharma India Ltd. witnessed a sharp rise of 8.26% on October 7, trading at ₹8,051. The stock opened at ₹7,440, surged to an intraday high of ₹8,129.95, and has been moving positively in early trade. The surge aligns with the company’s current focus on clinical trials and various cancer-related projects in India.
Key Developments and Outlook
- Global Expansion Plans: AstraZeneca, the British drug major, is actively conducting several clinical trials and cancer-related research initiatives in India, aiming to leverage advanced technologies to accelerate the launch of its global products.
- Sanjeev Panchal’s Insights: In a recent interview, Sanjeev Panchal, Managing Director and Country President of AstraZeneca Pharma India, shared insights into the company’s global and Indian strategies. AstraZeneca aims to achieve $80 billion in revenue globally by 2030, and India is expected to play a significant role in this growth. Last year, the company recorded global sales of around $45 billion, with nearly $10 billion invested in R&D.
Market Performance
- Day Range: ₹7,440 – ₹8,129.95
- 52-Week Range: ₹4,475 – ₹8,137.50 (showcasing a new high within the year)
- Market Cap: ₹201.36 billion
- P/E Ratio: 210.04
- Dividend Yield: 0.30%
India’s Contribution to Growth
India is expected to be a strategic market for AstraZeneca as it contributes to the company’s broader objective of achieving $80 billion in global revenue by 2030. The ongoing trials and focus on cancer therapies align with the company’s global priorities and underline the significant potential for growth within the Indian pharmaceutical market.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.